The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial-Reference-Cited by-同舟云学术

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial

Published:2022-11 Issue:11 Volume:28 Page:750.e1-750.e6
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Perales Miguel-Angel^ORCID,Kuruvilla John,Snider Julia Thornton,Vadgama Sachin^ORCID,Blissett Rob,El-Moustaid Fadoua^ORCID,Smith Nathaniel J.,Patel Anik R.,Johnston Patrick B.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference31 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

2. Diffuse large B-cell lymphoma;Sehn;N Engl J Med,2021

3. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD Study;van Imhoff;J Clin Oncol,2017

4. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017

5. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma;Schuster;N Engl J Med,2019

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

2. SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain;Cancers;2024-06-22

4. Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma;Nature Communications;2024-06-18

5. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States;Journal of Medical Economics;2024-06-06